TTR and polyneuropathy: ASO-mediated degradation occurs via the enzyme RNase H. The ASO therapy Inotersen (33), like Patisiran, binds to both wild-type and mutant TTR, induces a measurable decrease in mutant TTR level, and also received FDA-approval for the treatment of hATTR-associated polyneuropathy.